Article Text

PDF

S124 Derivation and validation of the bronchiectasis severity index: an international multicentre observational study
  1. JD Chalmers1,
  2. P Goeminne2,
  3. S Aliberti1,
  4. M McDonnell3,
  5. S Lonzi4,
  6. J Davidson3,
  7. L Poppelwell1,
  8. W Salih1,
  9. A Pesci4,
  10. L Dupont2,
  11. TC Fardon1,
  12. A De Soyza3,
  13. AT Hill5
  1. 1University of Dundee, Dundee, UK
  2. 2University Hospital Gasthuisberg, Leuven, Belgium
  3. 3University of Newcastle, Newcastle, UK
  4. 4University of Milan Bicocca, Monza, Italy
  5. 5Royal Infirmary of Edinburgh, Edinburgh, UK

Abstract

Introduction There are no risk stratification tools for morbidity and mortality in bronchiectasis. As more treatments become available, it is important to identify patients at risk of exacerbations, hospital admissions and mortality to target novel therapies.

Methods A prospective observational study at a specialist bronchiectasis clinic in Edinburgh, UK was used to derive a bronchiectasis severity index using cox-proportional hazards regression to identify independent predictors of mortality and hospital admission over 4 years follow-up. Averaged ß-coefficients were used to award points for each independent variable and the discrimination of a derived score was tested using the area under the receiver operator characteristic curve (AUC). The score was validated in independent cohorts from Dundee, UK (N = 218), Leuven, Belgium (N = 253), Monza, Italy (N = 105) and Newcastle, UK (N = 126).

Results 608 patients were included in the derivation cohort. Independent predictors of future hospital admissions were prior hospital admissions hazard ratio (HR) 13.5 (9.40–19.46), MRC dyspnoea score > 4, HR 2.42 (1.66–3.52), FEV1 <30% predicted HR 1.52 (1.03–2.25), Pseudomonas aeruginosa colonisation HR 2.16 (1.36–3.43), colonisation with other organisms HR 1.66 (1.12–2.44) and > 3 lobes involved on HRCT HR 1.48 (1.02–2.15). In the model for mortality, independent predictors were Age >70 years 8.57 (1.15–63.63), FEV1 <30% predicted HR 4.47 (1.60–12.53), prior hospital admissions HR 2.43 (1.30–4.53) and 3 or more exacerbations per year prior to the study HR 2.03 (1.02–4.03).

The bronchiectasis severity index derived from these models was composed of prior hospitalisation (5 points), MRC dyspnoea score (0–3 points), FEV1 (0–3 points), bacterial colonisation (0- 3 points) Age (0–6 points) BMI <18.5 (2 points) Exacerbation frequency (0–2 points) and radiological extent (1 point). The AUC for mortality was 0.80 (0.74–0.86) and the AUC for hospitalisation was 0.88 (0.84–0.91). There was a clear difference in exacerbation frequency and quality of life using the St. Georges Respiratory Questionnaire between patients classified as low, intermediate and high risk by the score (p < 0.0001 for all comparisons).

In the validation cohorts, the AUC for mortality ranged from 0.81–0.84 and for hospitalisation was AUC 0.80–0.88.

Conclusions The bronchiectasis severity index identifies patients at risk of future mortality, hospital admissions and exacerbations.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.